Loading...
Market
What will be the primary funding source for the human trials of the new HIV treatment using a molecular mimic by December 31, 2024?
2
Resolution / Starting Odds
Government grants • 25%
Pharmaceutical companies • 25%
Private investors • 25%
Non-profit organizations • 25%
Official announcements or publications from the research team or medical journals
Story
Scientists Develop New HIV Treatment Using Molecular Mimic, Reducing Virus 1,000-Fold
Aug 8, 2024, 08:37 PM
Scientists have developed a new experimental treatment against HIV, involving a molecular mimic that invades cells and steals essential proteins from the virus. This engineered virus, described as a 'molecular parasite', lacks the genes needed for replication, thereby using the replication machinery of wildtype HIV to crowd it out and stop it from multiplying. Promising results have been observed in monkeys, with a single shot reducing HIV levels 1,000-fold. Researchers plan to test this new therapy in a few people with HIV.
View original story
Similar markets
Yes • 50%
No • 50%
Fully funded • 25%
Partially funded • 25%
Not funded • 25%
Other • 25%
Government grants • 25%
Private sector • 25%
Non-profit organizations • 25%
University funding • 25%
Government grants • 25%
Private investment • 25%
Pharmaceutical partnership • 25%
University funding • 25%
Government grants • 25%
Private investors • 25%
Pharmaceutical companies • 25%
Non-profit organizations • 25%
Global Fund • 25%
PEPFAR • 25%
Gilead Sciences • 25%
Other • 25%
National Institutes of Health (NIH) • 25%
Centers for Disease Control and Prevention (CDC) • 25%
Private Foundations • 25%
Other • 25%
Government grants • 25%
Private investment • 25%
Pharmaceutical companies • 25%
Academic institutions • 25%
National Institutes of Health (NIH) • 25%
Bill & Melinda Gates Foundation • 25%
Wellcome Trust • 25%
Howard Hughes Medical Institute • 25%
Government grants • 25%
Private donations • 25%
Pharmaceutical companies • 25%
International organizations • 25%
Government grants • 25%
Private companies • 25%
Non-profits • 25%
Universities • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Gilead Sciences • 25%
Other • 25%